U.S. health regulators are warning consumers not to use more than two dozen varieties of over-the-counter eyedrops because of the risk of infections that could lead to blindness.

The Food and Drug Administration advisory applies to lubricating drops sold by six companies, including CVS Health, Target, Rite Aid and Cardinal Health. Consumers should stop using the products immediately and avoid purchasing any that remain on pharmacy and store shelves, the FDA said in a statement Friday.

The agency asked the companies to recall their products last week, because FDA inspectors found unsanitary conditions and bacteria at the facility producing the drops. The FDA did not disclose the location of the factory or when it was inspected.

No injuries related to the products had been reported at the time of the announcement, but the FDA encouraged doctors and patients to submit cases through the agency’s online reporting system.

Earlier this year, federal officials linked an outbreak of drug-resistant bacteria to eyedrops from two companies, EzriCare and Delsam Pharma. More than 80 people in the U.S. tested positive for eye infections from the rare bacterial strain, according to the most recent update from the Centers for Disease Control and Prevention.

After the products were recalled in February, health inspectors visited the manufacturing plant in India that made the eyedrops and uncovered problems with how they were made and tested, including inadequate sterility measures.

Share:
More In Science
Lawmakers Look Into Bitcoin Mining Companies' Energy Use
Democratic lawmakers are now calling on Bitcoin mining companies in the U.S. to assess how much electricity they use and how it could all potentially impact residents and the environment in the near future. Since its conception, crypto mining has been at the center of a debate. The question is: Is crypto mining playing a key role in renewable energy or could it totally derail U.S. climate goals? Host of The Wendy O show Wendy O, joined Cheddar to discuss more.
Athletic Greens Raises $115 Million to Expand Footprint of Nutritional Drink
Nutritional supplement beverage company Athletic Greens has achieved unicorn status. The company announced a new $115 million funding round, bringing its valuation to $1.2 billion. The company's flagship product AG1 combines 75 different vitamins, minerals, and other nutrients into one daily serving. Athletic Greens says it is poised to reach the millions of consumers who are currently driving the health and wellness market's exponential growth. Athletic Greens founder and CEO Chris Ashenden joins Cheddar News' Closing Bell to discuss.
Northeast Recovering From Weekend Snow Storm
A powerful winter storm hit the Northeast over the weekend leaving 100,000 New Yorkers in the dark as well as snowfall up to 30.9 inches in parts of Massachusetts. The nor'easter hit with blizzard conditions of wind speed and poor visibility.
Beyond Meat Expands McDonald's Deal As Fast Food Reign Continues
Plant-based meat giant Beyond Meat's reign over the fast food world continues, as McDonald's announced that it is expanding its test of Beyond's McPlant burger, to nearly 600 restaurants, an increase from the eight that it's been testing in since November. This comes less than two weeks after Beyond Fried Chicken made its nationwide debut at KFC restaurants, the first time that plant based chicken has been widely distributed in a fast food capacity. Arun Sundaram, Senior Equity Analyst at CFRA Research explains why these latest collaborations may be proof that Beyond Meat products could slowly be becoming an unlikely staple in the fast food and chain restaurant world as consumers opt for more healthy food options.
BD Veritor Hopes to Take 'Guesswork' Out With Smartphone-Enabled COVID Test
BD Veritor is a variation of the at-home COVID test that uses a smartphone to interpret the results. The test is taken via a nose swab test strip that is then scanned by your phone’s camera with the result clearly displayed as positive or negative. James Walker, vice president of integrated diagnostics USA for BD, joined Cheddar to discuss how the test hopefully takes the "guesswork out of testing." Walker also went into what BD is doing to deal with the surging demand for at-home tests amid the omicron spread. "While we don't disclose how much we produce, we have capacity to manufacture up to 12 million rapid antigen tests per month and are delivering on our commitments to distributors and retailers," he said.
Load More